Spots Global Cancer Trial Database for urologic diseases
Every month we try and update this database with for urologic diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | NCT04555343 | Urologic Diseas... Prostate Cancer Bladder Cancer Urinary Retenti... Hematuria Nurse Physician... Nurse's Role Patient Satisfa... | Tranexamic acid | 18 Years - | Fraser Health | |
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| HPI Effect in Robotic Urological Surgery on AKI | NCT06051162 | Prostate Cancer Renal Cancer Urologic Diseas... | BP management w... | 19 Years - | Ewha Womans University Mokdong Hospital | |
| A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery | NCT03010813 | Colorectal Neop... Urologic Neopla... Urologic Diseas... Nasopharyngeal ... Oropharyngeal N... Oral Neoplasms Hypopharyngeal ... Laryngeal Neopl... ENT Diseases | Robotic single ... | 18 Years - | Chinese University of Hong Kong | |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | NCT00384891 | Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy | NCT02765594 | Primary IgA Nep... | Hydroxychloroqu... Valsartan | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| Renal Hypothermia During Partial Nephrectomy | NCT01529658 | Renal Impairmen... Kidney Diseases Urologic Diseas... Cancer Hypothermia Kidney Cancer | Renal hypotherm... | 18 Years - | Ottawa Hospital Research Institute | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | NCT04555343 | Urologic Diseas... Prostate Cancer Bladder Cancer Urinary Retenti... Hematuria Nurse Physician... Nurse's Role Patient Satisfa... | Tranexamic acid | 18 Years - | Fraser Health | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies | NCT06187870 | Urologic Diseas... Urologic Cancer Infertility | Collection of b... | 18 Years - | IRCCS San Raffaele | |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | NCT03933826 | Bladder Cancer Cancer of the B... Non-muscle Inva... | 18 Years - | University of Washington | ||
| HPI Effect in Robotic Urological Surgery on AKI | NCT06051162 | Prostate Cancer Renal Cancer Urologic Diseas... | BP management w... | 19 Years - | Ewha Womans University Mokdong Hospital | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies | NCT06187870 | Urologic Diseas... Urologic Cancer Infertility | Collection of b... | 18 Years - | IRCCS San Raffaele | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | NCT02301117 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| Connected Catheter- Safety and Effectiveness Study | NCT03843073 | Urinary Retenti... Neurogenic Blad... Urologic Diseas... | Connected Urina... | 18 Years - | Spinal Singularity | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | NCT02307487 | Bladder Cancer Neoplasms Urinary Bladder... Urologic Diseas... | 120 mg MMC in 9... 140 mg MMC in 9... 160 mg MMC in 9... 120 mg MMC in 6... 140 mg MMC in 6... 160 mg MMC in 6... | 18 Years - | UroGen Pharma Ltd. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients | NCT02891460 | Urinary Bladder... Urologic Neopla... Neoplasms Urinary Bladder... Urologic Diseas... | 40 mg MMC in 40... 80 mg MMC in 40... | 18 Years - | UroGen Pharma Ltd. | |
| A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | NCT00753415 | Non-Small Cell ... Breast Cancer Melanoma Upper GI Tract ... Colon Carcinoma Renal Cell Carc... Bladder Carcino... Prostate Cancer | V935 V934-EP | 18 Years - | Merck Sharp & Dohme LLC | |
| Renal Hypothermia During Partial Nephrectomy | NCT01529658 | Renal Impairmen... Kidney Diseases Urologic Diseas... Cancer Hypothermia Kidney Cancer | Renal hypotherm... | 18 Years - | Ottawa Hospital Research Institute | |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | NCT02543645 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms by Hi... Neoplasms Clear-cell Meta... Melanoma Triple Negative... Bladder Cancer Head and Neck C... Non-small Cell ... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China | |
| Rare Cystic Benign Adrenal Incidentalomas | NCT03739918 | Urologic Diseas... Adrenal Tumor | 18 Years - | Mansoura University | ||
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China | |
| Pelvic Floor Muscles Training in Men Undergoing Radiotherapy for Prostate Cancer: Randomized Controlled Trial | NCT01762956 | Prostate Cancer Urologic Diseas... | Pelvic floor mu... | 45 Years - | University of Sao Paulo |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
